About ImmunoGen
ImmunoGen is a company based in Waltham (United States) founded in 1981 was acquired by AbbVie in November 2023.. ImmunoGen has raised $126 million across 5 funding rounds from investors including AbbVie. The company has 106 employees as of December 31, 2022. ImmunoGen operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter Waltham, United States
- Employees 106 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of ImmunoGen
ImmunoGen has successfully raised a total of $126M across 5 strategic funding rounds. The most recent funding activity was a Private Equity Round round of $100 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Private Equity Round — $100.0M
-
First Round
First Round
(15 Jun 2011)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2016 | Amount | Private Equity Round - ImmunoGen | Valuation |
investors |
|
| Dec, 2011 | Amount | Private Equity Round - ImmunoGen | Valuation |
investors |
|
| Nov, 2011 | Amount | Angel Round - ImmunoGen | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ImmunoGen
ImmunoGen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include AbbVie. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ImmunoGen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ImmunoGen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Immunogen Comparisons
Competitors of ImmunoGen
ImmunoGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| domain | founded_year | HQ Location |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Immunogen
Frequently Asked Questions about ImmunoGen
When was ImmunoGen founded?
ImmunoGen was founded in 1981 and raised its 1st funding round 30 years after it was founded.
Where is ImmunoGen located?
ImmunoGen is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Who is the current CEO of ImmunoGen?
Mark Enyedy is the current CEO of ImmunoGen.
Is ImmunoGen a funded company?
ImmunoGen is a funded company, having raised a total of $126M across 5 funding rounds to date. The company's 1st funding round was a Angel Round of $1M, raised on Jun 15, 2011.
How many employees does ImmunoGen have?
As of Dec 31, 2022, the latest employee count at ImmunoGen is 106.
What is the annual revenue of ImmunoGen?
Annual revenue of ImmunoGen is $108.78M as on Dec 31, 2022.
What does ImmunoGen do?
ImmunoGen was founded in 1981 and is headquartered in Waltham, United States. Targeted anticancer therapeutics are developed using proprietary antibody-drug conjugate technology within the biotechnology sector. Operations focus on creating treatments for solid tumors, including the lead candidate Mirvetuximab Soravtansine for folate receptor α-positive ovarian cancers. The technology is incorporated into Roches Kadcyla for HER2-positive metastatic breast cancer and is licensed to various healthcare companies for further applications.
Who are the top competitors of ImmunoGen?
ImmunoGen's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Syndax.
Who are ImmunoGen's investors?
ImmunoGen has 1 investor. Key investors include AbbVie.